pms-Sumatriptan Drug Interactions

Drug-Drug Interactions: Single-dose pharmacokinetic drug interaction studies have not shown evidence of interactions with propranolol, flunarizine, pizotifen or alcohol. Multiple-dose interaction studies have not been performed.
Ergot-Containing Drugs: Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because there is a theoretical basis for these effects being additive, ergot-containing or ergot-type medications (like dihydroergotamine or methysergide) are contraindicated within 24 hours of pms-SUMATRIPTAN administration (see Contraindications).
MAO Inhibitors: In studies conducted in a limited number of patients, MAO inhibitors reduce sumatriptan clearance, significantly increasing systemic exposure. Therefore, the use of pms-SUMATRIPTAN in patients receiving MAO inhibitors is contraindicated (see Pharmacology: Pharmacokinetics: Absorption/Metabolism under Actions; Contraindications).
Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs): Cases of life-threatening serotonin syndrome have been reported during combined use of selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) and triptans (see Neurologic: Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) and Serotonin Syndrome under Precautions).
Other 5-HT₁ agonists: The administration of sumatriptan succinate with other 5-HT₁ agonists has not been evaluated in migraine patients. As an increased risk of coronary vasospasm is a theoretical possibility with coadministration of 5-HT₁ agonists, use of these drugs within 24 hours of each other is contraindicated.
Drug-Laboratory Test Interactions: Sumatriptan succinate is not known to interfere with commonly employed clinical laboratory tests.